Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation
Hayder Kadhim, Consultant Cardiologist at Region Östergötland, shared a post on LinkedIn:
”I am pleased and honored to present our latest study as a poster at the prestigious ESOC Conference in Maastricht.
Our research explores risk factors associated with oral anticoagulant (OAC) interruptions in patients with non-valvular atrial fibrillation (NVAF), including both temporary and permanent discontinuations.
We also examine treatment pattern changes across different OAC types and dosing strategies, and compare clinical outcomes between patients who persist with therapy and those who discontinue.
This work is based on high-quality Swedish national registers, including AURICULA, which uniquely enabled us to identify the exact dates of treatment discontinuation and generate robust real-world evidence.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention